San Diego

The trials here

What the 44 trials at this site are about, from their registry records.

Conditions

• Asthma12 trials
• Lung cancer8 trials
• Prostate cancer7 trials
• Chronic kidney disease3 trials
• Heart failure3 trials
• Kidney cancer3 trials
• Bladder cancer2 trials
• COPD2 trials
• Endometrial cancer2 trials
• Gastric and oesophageal cancer2 trials
• Liver and biliary tract cancer2 trials
• Ovarian cancer2 trials
• and 18 more

Phase

• Phase 334 trials
• Phase 13 trials
• Phase 23 trials
• Phase 41 trial

Status

• Recruiting11 trials
• Completed10 trials
• Active, not recruiting9 trials
• Not yet recruiting5 trials
• Terminated4 trials
• Withdrawn3 trials
• Suspended2 trials

Lead sponsor

• AstraZeneca40 trials
• Arcus Biosciences, Inc.2 trials
• Alexion Pharmaceuticals, Inc.1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

  NCT07525375· Phase 2· AstraZeneca· Source

• Recruiting

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· Phase 3· AstraZeneca· Source

• Recruiting

  DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

  Contact: Medical Director

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06879041· Phase 1· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· AstraZeneca· Source

• Recruiting

  Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT06350097· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· Phase 3· AstraZeneca· Source

• Active, not recruiting

  BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

  NCT05943106· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  NCT05536141· Phase 1· Arcus Biosciences, Inc.· Source

  Contact: Medical Director

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

  NCT05221840· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Asthma3 recruiting
• Heart failure3 recruiting
• Kidney cancer3 recruiting
• Prostate cancer3 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Completed

  A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

  NCT06644924· Phase 2· AstraZeneca· Source

• Completed

  Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

  NCT06563102· Phase 4· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Completed

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· Phase 2· AstraZeneca· Source

• Completed

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· Phase 3· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source

• Completed

  A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

  NCT04483947· Phase 1· AstraZeneca· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  Benralizumab Pregnancy Exposure Study

  NCT03794999· AstraZeneca· Source

• Completed

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source